{
  "$schema": "folio-library-entry/v1",
  "id": "10665-385346",
  "blocks": [
    {
      "id": "library/10665-385346/blocks/prose-page-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 1",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/page-001.md",
      "narrative": null,
      "content": "Research article EMH] - Vol. 25 No. 10 - 2019\n\nCost-effectiveness of introducing the pneumococcal conjugate\nvaccine for children under 5 years in the Islamic Republic of Iran\n\nKhadijeh Ezoji’,7, Mohsen Yaghoubi?, Marzieh Nojomi*, Sussan Mahmoody*, Seyed Mohsen Zahraie’, Maziar Moradi-Lakeh*, Sedigheh R. Tabatabaei®\nand Abdollah Karimi®\n\n‘Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Islamic Republic of Iran. *De-\npartment of Community Medicine, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran. *School",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opening page of a 2019 Eastern Mediterranean Health Journal article on the cost-effectiveness of introducing the 13-valent pneumococcal conjugate vaccine (PCV-13) for children under 5 in the Islamic Republic of Iran, with authors and affiliations. The abstract describes use of the TRIVAC decision support model to estimate costs and disability-adjusted life years averted for pneumonia, meningitis, otitis media and other pneumococcal disease. The introduction notes that vaccinating young children also reduces disease indirectly by cutting nasopharyngeal carriage.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 2",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/page-002.md",
      "narrative": null,
      "content": "Research article\n\nEMH] - Vol. 25 No. 10 - 2019\n\nAfterrunning several clinical trials in different regions\nof the world, PCV-10 and PCV-13 have been introduced\nin the national vaccination programmes of more than\n100 countries, including many low- and middle-income\ndeveloping countries. These vaccines have been found to\nbe cost-effective, especially in developing countries with\nlimited health care resources (3,8,9), and can be safely\nadministered at the same time as other vaccines without\ninterference (9).\n\nThe pneumococcal vaccine is not part of the childhood\nimmunization programme in the Islam",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that PCV-10 and PCV-13 are used in over 100 countries and that pneumococcal vaccine is not in Iran's schedule, although acute respiratory infection was the fourth leading cause of under-5 deaths in 2013. It describes the TRIVAC model, an Excel-based static cohort model developed by LSHTM with PAHO, ProVac and WHO, and the disease states considered. It then outlines the sources used for disease burden and vaccine efficacy inputs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 3",
      "pageStart": 3,
      "pageEnd": 3,
      "target": "../sections/page-003.md",
      "narrative": null,
      "content": "Research article\n\nEMH] - Vol. 25 No. 10 - 2019\n\nSerotype coverage\n\nBased on a systematic evaluation of global serotype cov-\nerage, we assumed that 70% of pneumococcal acute oti-\ntis media, pneumonia, meningitis, and non-pneumonia,\nnon-meningitis infection were covered by the vaccine in\nthe Islamic Republic of Iran (25,26).\n\nCost estimation\nVaccination programme costs\n\nWe used WHO guidelines to calculate the costs of intro-\n\nducing PCV-13 into the current national immunization\nprogramme (27). The price of each dose (US$ 20) was ob-\ntained from the local representative of the vaccine manu-\nfactu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the assumption that 70% of pneumococcal disease is covered by vaccine serotypes and how programme costs were estimated, using a vaccine price of US$ 20 per dose plus system costs. A table gives the estimated burden inputs, including incidence, case fatality, sequelae, disability weights and age distribution, with high and low scenarios.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 4",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/page-004.md",
      "narrative": null,
      "content": "Research article EMH] - Vol. 25 No. 10 - 2019\n\nTable 2 Estimated vaccine coverage in the Islamic Republic of Iran used for the TRIVAC model\n\nScenario\n\nVariable Estimate (%) Source/s\nHigh Low\n\nCoverage of DTP1 by age in 2014 (proxy for PCV\n\ndoses given with DTP1)\n3m 97.2 NA NA MoHME\n6m 98.5 NA NA MoHME\nom 98.9 NA NA MoHME\n2m 99.3 NA NA MoHME\n24m 100.0 NA NA MoHME\n\nCoverage of DTP2 by age in 2014 (proxy for PCV\n\ndoses given with DTP2)\n3m 0.0 NA NA MoHME\n6m 98.3 NA NA MoHME\nom 98.6 NA NA MoHME\n2m 99.1 NA NA MoHME\n24m 100.0 NA NA MoHME\n\nCoverage of DTP3 by age in 2014 (proxy for PCV\n\ndoses given w",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents tables of the vaccine coverage inputs, based on DTP coverage by age in 2014, and the vaccine efficacy, serotype coverage and other assumptions used in the TRIVAC model for PCV-13.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 5",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/page-005.md",
      "narrative": null,
      "content": "Research article\n\nEMH] - Vol. 25 No. 10 - 2019\n\nTable 4 Data used for variables in the TRIVAC model to estimate programme costs of pneumococcal conjugate vaccine-13\n\nVariable\n\nEstimate\n\nScenario\nSource/s\n\nProjected vaccine price per dose (US$)\n\n2014 20.00\n2015 18.00\n2016 16.20\n2017 14.58\n2018 13.12\n2019 1.81\n2020 10.63\n2021 9.57\n2022 8.61\n2023 7-75\nOther vaccine dose costs\nInternational handling (% of vaccine price) 3.0\nInternational delivery (% of vaccine price) 2.0\nWastage (e.g. % of doses discarded) 5.0\nIncremental system cost of introduction per dose (US$) 1.05\n\nHigh Low\n\n35.00 14.24 Local",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a table of programme cost inputs, including projected vaccine prices falling from US$ 20 in 2014, handling, wastage and system costs. It describes assumptions on hospitalization and outpatient care and the split between public and private providers. Costs were converted at 35 000 rials per US dollar, and the sensitivity analysis approach is introduced.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 6",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/page-006.md",
      "narrative": null,
      "content": "Research article\n\nEMH] - Vol. 25 No. 10 - 2019\n\nTable 5 Data used for variables in the TRIVAC model to estimate health service utilization and costs (all costs are for 2014)\n\nScenario\nVariable Estimate Source/s\nHigh Low\nOutpatient visits\nOutpatient visits per disease episode\nAll-cause acute otitis media 1 1 0.7 MoHME\nPneumococcal pneumonia 0.47 0.6 0.2 MoHME\nPneumococcal meningitis 0.05, 0.08 0.02 MoHME\nPneumococcal NPNM 0.05 0.08 0.02 MoHME\nGovernment cost per outpatient visit (US$)\nAll-cause acute otitis media 2.6 3 2.2 Calculated\nPneumococcal pneumonia 74 8 6.8 Calculated\nPneumococcal menin",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a table of health service use and cost inputs per outpatient visit and inpatient admission, from government and household perspectives. Results begin, reporting that PCV-13 would avert about 10 000 deaths over 2014–2023 and be highly cost-effective at about US$ 1890 and US$ 1538 per DALY averted for government and society.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 7",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/page-007.md",
      "narrative": null,
      "content": "Research article\n\nEMH] - Vol. 25 No. 10 - 2019\n\nTable 6 Estimated health burden of pneumococcal diseases with and without PCV-13, and discounted health benefitsa of PCV-13\nfor 10 cohorts vaccinated over the period 2014-2023\n\nVariable\n\nCases of pneumococcal disease in children < 5 years (no.)\nTotal cases\n\nAll-cause acute otitis media\n\nPneumococcal pneumonia\n\nPneumococcal meningitis\n\nPneumococcal NPNM\nOutpatient visits for pneumococcal disease in children <5 years (no.)\nTotal visits\n\nAll-cause acute otitis media\n\nPneumococcal pneumonia\n\nPneumococcal meningitis\n\nPneumococcal NPNM\nHospital admissi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives a table of pneumococcal cases, visits, admissions, deaths and DALYs with and without PCV-13 for ten cohorts. It describes the sensitivity analysis of 19 scenarios, including the most and least favourable, and begins comparing results with WHO cost-effectiveness benchmarks.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 8",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../sections/page-008.md",
      "narrative": null,
      "content": "Research article\n\nEMH] - Vol. 25 No. 10 - 2019\n\nDALY averted of less than three times the gross domestic\nproduct per capita should be considered cost-effective (30).\n\nWe estimated that vaccination could prevent more\nthan 4.5 million cases of pneumococcal-associated disease\nover the period 2014-2023. A national immunization\nprogramme with PCV-13 was estimated to prevent 38%\nof all deaths from pneumococcal diseases. The economic\nburden to society of pneumococcal diseases in children\nunder 5 years in the Islamic Republic of Iran during\n2014-2023 was calculated to be US$ 447.78 million; about\n34%",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discusses the results: vaccination could prevent over 4.5 million cases and 38% of pneumococcal deaths, and avert about a third of the societal economic burden over 2014–2023. It compares findings with cost-effectiveness studies from Egypt, Peru and Croatia. It notes limitations, including limited private-sector data, followed by a cost table.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/figure-vfig-p009",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../figures/vfig-p009.webp",
      "narrative": "draft",
      "content": "The top is the lower part of a table comparing government and society perspectives for PCV-13 introduction: net cost US$ 573.31 million vs 466.53 million, DALYs averted 303.34 thousand in both, US$ per DALY averted 1 890 vs 1 538, against thresholds of 1 × GDP per capita (4 526) and 3 × GDP per capita (13 578). Below, Figure 1 is a horizontal bar chart titled “Sensitivity Analysis” with paired dark-blue and light-blue bars for about 20 scenarios, from “Least favourable” (longest bars) through “Base case scenario” to “Most favourable”, marked with a red arrow labelled “Cost saving”. Dashed vertical lines mark 1*GDP and 3*GDP; all bars stay left of the 1*GDP line, and no axis values or legend are visible.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-385346/blocks/prose-page-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 9",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/page-009.md",
      "narrative": null,
      "content": "Research article\n\nEMH] - Vol. 25 No. 10 - 2019\n\nTable 8 Discounted cost-effectiveness* of PCV-13 (10 cohorts vaccinated over the period 2014-2023) compared with no vaccination\n\nfor the government and society\n\nGovernment Society\n\nNet cost of PCV-13 introduction (million US$)\nCost of vaccine introduction\nHealth service costs avoided\nDALYs averted (000s)\nYears lived with disability averted\nYears of life lost averted\nUSs per DALY averted\nCost-effectiveness threshold (US$)\n1x GDP per capita (2012)b\n3 x GDP per capita (2012)c\n\n573.31 466.53\n618.85 618.85\n45.54 152.32\n303.34, 303.34\n7.88 7.88\n295.46",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the table of discounted cost-effectiveness of PCV-13 for government and society against GDP-based thresholds and a figure of the sensitivity analysis scenarios. It concludes that PCV-13 would be a high-impact intervention for Iran and that evidence should guide new vaccine introduction.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 10",
      "pageStart": 10,
      "pageEnd": 10,
      "target": "../sections/page-010.md",
      "narrative": null,
      "content": "Research article EMH] - Vol. 25 No. 10 - 2019\n\nAcknowledgments\n\nWe are grateful to the Iranian Ministry of Health and Medical Education, especially the Center for Communicable\nDisease Control, and the WHO country office in the Islamic Republic of Iran. We thank all advisers and colleagues, espe-\ncially Gabriela Felix, for their technical support.\n\nFunding: This work was supported by the ProVac International Working Group, which is funded entirely by a grant from\nthe Bill & Melinda Gates Foundation (grant number: OPP1032888).\n\nCompeting interests: None declared.\n\nRapport coit-efficacité de l’in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A page from a 2019 Eastern Mediterranean Health Journal article on introducing the 13-valent pneumococcal conjugate vaccine for children under five in the Islamic Republic of Iran, closing the English text with acknowledgements, funding from the ProVac International Working Group and a statement of no competing interests. It then gives French and Arabic abstracts: the TRIVAC model, using local cost data, estimated about 18.7 million pneumococcal cases over 2014–2023 without vaccination, of which the vaccine would prevent about 4.9 million, along with 105 802 hospitalizations and 9997 deaths. The authors judge the vaccine cost-effective against WHO thresholds; the French and Arabic OCR is noticeably garbled, especially accents and Arabic numerals, and the Arabic abstract is cut off.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 11",
      "pageStart": 11,
      "pageEnd": 11,
      "target": "../sections/page-011.md",
      "narrative": null,
      "content": "Research article EMH] - Vol. 25 No. 10 - 2019\n\nJot OF Lt ys PCV V9 CU plas oly, UBL plaszel O99 oye CV TT LY VE ye) Sl ee he V9 JE (FAV AG bbl\nbg EVAN £04 cLL) dea IN OSV lel V4 AEF oS LID 48 Sly Ul Sp DE EV AE RLS O50\nJs BES ML SU spe ee Byes CLEVE T LES lel sls SS OLS ye dell oe ssl TOTS bball\nBb Die AA AV. 3 patie J po SVL oye VP ONY Cad Sad egal as Li. By DL VATA bye piteell Lis ye YAV qos\n\npel gee ope SEE Se IST LS ed GY 50 VOT LS ATL go VAG* floes otras He Sol) LILSYI WEY EL © 18\nSI be LEY Ca Daal\n\nJaLSU PCV-V¥ CU Sle] oS GAUSS Sam oye ILRI pends ALL Seca Lala bp Ce gl all El ote By sche",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Contains the end of the garbled Arabic abstract, which is unreadable in the extracted text, followed by the start of the reference list citing global pneumococcal burden estimates, Cochrane and cost-effectiveness studies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-385346/blocks/prose-page-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 12",
      "pageStart": 12,
      "pageEnd": 12,
      "target": "../sections/page-012.md",
      "narrative": null,
      "content": "Research article EMH] - Vol. 25 No. 10 - 2019\n\n21.\n\n22.\n\n23.\n\n24.\n\n25.\n\n26.\n\n27.\n\n28.\n\n29.\n30.\n\n31.\n\nGriffiths UK. Haemophilus influenzae type b vaccine in low- and middle-income countries: impact, costs and incremen-\ntal cost-utility [PhD thesis].London: London School of Hygiene and Tropical Medicine; 2012. doi: https://doi.org/10.17037/\nPUBS.02869500\n\nHortal M, Estevan M, Iraola I, De Mucio B. A population-based assessment of the disease burden of consolidated pneumonia in\nhospitalized children under five years of age. Int J Infect Dis. 2007;11(3):273-7.\n\nPavia M, Bianco A, Nobile CG, Marine",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The end of the reference list for the PCV-13 cost-effectiveness article, citing studies on vaccine efficacy, serotypes, WHO guidance on cost-effectiveness analysis and a Croatian economic evaluation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
